SCHEMBL3297763

SCHEMBL3297763

CN1CCN(C(=O)C2CCC(c3ccc(N)cc3)CC2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.53
LMNA P02545 1/20 0.48
HSD11B1 P28845 1/20 0.47
KDM1A O60341 1/20 0.47
MAOB P27338 1/20 0.47
NAMPT P43490 3/20 0.44
POLB P06746 1/20 0.43
SOS1 Q07889 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CNR1 P21554 1/20 0.42
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL520567 0.89 NAMPT (0.55) HTTKDM1ANAMPTHDAC3HDAC4
SCHEMBL3304712 0.87 HPGD (0.55) HTTHSD11B1TDP1HDAC3HDAC1
SCHEMBL3634211 0.86 SLC18A3 (0.49) NAMPTTDP1CNR1HTR2B
SCHEMBL3297761 0.86 HTT (0.50) HTTLMNAHSD11B1KDM1AMAOB
SCHEMBL3303482 0.84 DGAT1 (0.48) NAMPTTDP1CNR1HTR2B
SCHEMBL521101 0.82 KCNH2 (0.52) LMNAHSD11B1KDM1AMAOBNAMPT
SCHEMBL3810068 0.81 SLC18A3 (0.54) NAMPTCNR1TSHRHTR2BKMT2A
SCHEMBL520513 0.80 KMT2A (0.58) HTTLMNAHSD11B1NAMPTPOLB
SCHEMBL2075903 0.78 HTT (0.81) HTTLMNAHSD11B1TDP1TSHR
SCHEMBL3816677 0.77 SLC18A3 (0.46) NAMPTHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093733-A1 AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES PROSIDION LIMITED (GB) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093733-A1 AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES CPS1, GOT2, GPR119 HTT 2349/4885LMNA 3562/4885HSD11B1 753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.